CUX1
CUX1 (Homeobox protein cut-like 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Breast cancer and 5 more.
Overview
Transcription factor involved in the control of neuronal differentiation in the brain. Regulates dendrite development and branching, and dendritic spine formation in cortical layers II-III. Also involved in the control of synaptogenesis.
Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes affected pathway 0.95, literature 0.96, genetic association 0.67, somatic mutation 0.88, animal model 0.69). IntOGen calls it a driver in 7 cohorts (2 activating, 5 loss-of-function), covering Invasive Breast Carcinoma, Glioblastoma, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Melanoma, Pancreatic Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CUX1 (Homeobox protein cut-like 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Breast cancer and 5 more.
- 1 · What it is
CUX1 (Homeobox protein cut-like 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Transcription factor involved in the control of neuronal differentiation in the brain. Regulates dendrite development and branching, and dendritic spine formation in cortical layers II-III.
- 3 · How drugs use it
No product in this corpus aims at CUX1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:2557 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P39880 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000257923 (association with cancer (MONDO_0004992) 0.82; per-cancer scores at or above 0.5: colorectal cancer 0.50, gastric cancer 0.50, melanoma 0.61, acute lymphoblastic leukaemia 0.57, non-Hodgkin lymphoma 0.58, skin cancer 0.67 (GraphQL API, CC0)); IntOGen CUX1 (driver in 7 cohorts (Act 2, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription factor involved in the control of neuronal differentiation in the brain. Regulates dendrite development and branching, and dendritic spine formation in cortical layers II-III. Also involved in the control of synaptogenesis. In addition, it has probably a broad role in mammalian development as a repressor of developmentally regulated gene expression. May act by preventing binding of positively-activing CCAAT factors to promoters. Component of nf-munr repressor; binds to the matrix attachment regions (MARs) (5' and 3') of the immunoglobulin heavy chain enhancer. Location: Nucleus (UniProt). Locus 7q22.1 (HGNC).
- Skin cancer: Open Targets association 0.67 with skin cancer (MONDO_0002898)
- Leukaemia: Open Targets association 0.66 with leukaemia (MONDO_0005059)
- Breast cancer: Open Targets association 0.66 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Non-Hodgkin lymphoma: Open Targets association 0.58 with non-Hodgkin lymphoma (MONDO_0018908)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Thyroid cancer: IntOGen driver in 1 cohort (WDTC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CUX1" OR ABSTRACT:"CUX1" OR TITLE:"cut like homeobox 1" OR ABSTRACT:"cut like homeobox 1" OR TITLE:"Homeobox protein cut-like 1" OR ABSTRACT:"Homeobox protein cut-like 1" OR TITLE:"CDP1" OR ABSTRACT:"CDP1" OR TITLE:"Clox" OR ABSTRACT:"Clox" OR TITLE:"CDP/Cut" OR ABSTRACT:"CDP/Cut") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CUX1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetRUNX1T1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetPOLD1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetCBFA2T3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetSMAD3
Shares Thyroid cancer, Lung cancer (all types), Skin cancer (all types), Breast cancer (all types).
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetTP63
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetRRM2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetFCRL4
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.